Cargando…
1637. Safety Evaluation of the Novel Oral Polio Vaccine Type 2 during a National Supplementary Immunisation Activity in Uganda, a Multipronged Approach: January–March 2022
BACKGROUND: Data from clinical trials show that novel oral poliovirus vaccine type 2 (nOPV2) is safe. However, nOPV2 is under emergency use listing, and continued vaccine safety monitoring is required to support licensure and World Health Organization (WHO) prequalification. In January 2022, Uganda...
Autores principales: | Nsubuga, Fred, Gilani, Zunera, Tobolowsky, Farrell A, Longley, Ashley T, Greene, Sharon A, Ntale, Ismail, Hellen, Ndagije, Kisakye, Annet, Ampaire, Immaculate, Kyabayinze, Daniel, Gidudu, Jane F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677646/ http://dx.doi.org/10.1093/ofid/ofad500.1471 |
Ejemplares similares
-
Positive predictive value and effectiveness of measles case-based surveillance in Uganda, 2012-2015
por: Nsubuga, Fred, et al.
Publicado: (2017) -
Assessing the impact of polio supplementary immunisation activities on routine immunisation and health systems: a systematic review
por: Vassallo, Amy, et al.
Publicado: (2021) -
The Journalists Initiatives on Immunisation Against Polio and Improved Acceptance of the Polio Vaccine in Northern Nigeria 2007–2015
por: Warigon, Charity, et al.
Publicado: (2016) -
Richard Morton (1637-1698).
por: Trail, R R
Publicado: (1970) -
Jan Swammerdam (1637–1680). His Life and Works
por: Towers, Bernard
Publicado: (1969)